Ποια είναι η τιμή για Spectrum Pharmaceuticals, Inc. (SPPI)

Η τιμή για Spectrum Pharmaceuticals, Inc. (SPPI) είναι $1.03

Ποια είναι η κεφαλαιοποίηση αγοράς για Spectrum Pharmaceuticals, Inc. (SPPI)

Η κεφαλαιοποίηση αγοράς για Spectrum Pharmaceuticals, Inc. (SPPI) είναι $115.13M

Spectrum Pharmaceuticals, Inc. (SPPI) Τιμή και Κεφαλαιοποίηση Αγοράς

Spectrum Pharmaceuticals, Inc. operates as a biopharmaceutical firm, primarily engaged in the research, development, and market introduction of innovative drug products for cancer and blood disorders. Its robust pipeline features Eflapegrastim, an advanced, long-acting granulocyte colony-stimulating factor designed to address chemotherapy-induced neutropenia. Also under development is Poziotinib, a distinct irreversible tyrosine kinase inhibitor intended for non-small cell lung cancer tumors exhibiting various mutations. Furthermore, Anti-CD20-IFNa, an antibody-interferon fusion molecule targeting CD20, is progressing through Phase I development for patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. The company maintains key collaborative agreements, such as co-development, commercialization, and in-licensing arrangements with Hanmi Pharmaceutical Co. Ltd., a patent and technology license with The University of Texas M.D. Anderson Cancer Center, and an in-license pact with ImmunGene, Inc. Founded in 1987, and initially known as NeoTherapeutics, Inc. before its name change in December 2002, Spectrum Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Η τιμή για SPPI	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$46,621.61 $115.13M	NVDA	$5.211T	+4,526,270.13%
$40,675.81 $115.13M	AAPL	$4.547T	+3,949,007.36%
$37,238.07 $115.13M	GOOG	$4.162T	+3,615,247.00%
$32,141.59 $115.13M	MSFT	$3.593T	+3,120,442.98%
$24,985.25 $115.13M	AMZN	$2.793T	+2,425,652.74%

Η τιμή για SPPI

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$46,621.61 $115.13M